Identity and synonyms
GnRH/gonadorelin label: confirm molecule, salt and formulation.
Synonyms: Gonadorrlin (source spelling) · Gonadorelin acetate
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Peptide or peptide-derivative label; see identity
Supplied sequence or chemical reference
Mechanism
GnRH stimulates pituitary receptors and LH/FSH release; pulsatile versus continuous exposure profoundly changes response.
Evidence and critical reading
Reported scientific and empirical uses
Fertility and reproduction
Endocrine diagnostic/reproductive contexts; do not equate a catalog administration with specialized pulsatile delivery.
Human evidence
A retrospective human cohort of 66 functional hypothalamic amenorrhea patients evaluated pulsatile GnRH with favorable reproductive outcomes. It was not a trial of isolated catalog injections or a general hormonal “reset”.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
A retrospective human cohort of 66 functional hypothalamic amenorrhea patients evaluated pulsatile GnRH with favorable reproductive outcomes. It was not a trial of isolated catalog injections or a general hormonal “reset”.
A retrospective human cohort of 66 functional hypothalamic amenorrhea patients evaluated pulsatile GnRH with favorable reproductive outcomes. It was not a trial of isolated catalog injections or a general hormonal “reset”.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
This record does not verify FDA/EMA authorization of the commercial identity. Where a specific medicine/product exists, jurisdiction/indication are detailed in cited sources; they do not transfer to supplier material.
Adverse effects and unknowns
Gonadal axis, pregnancy, pituitary disease and other hormonal therapies change interpretation. Do not transfer mg, bovine protocols or triptorelin regimens.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID36378460 · Retrospective cohort
Functional hypothalamic amenorrhea, 212 cycles.
Pulsatile GnRH via SC pump.
Favorable reproductive outcomes in a 25-year cohort.
A clinically selected cohort does not validate isolated catalog administrations or a hormonal “reset”.
n = 66
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Gonadorelin · 1164 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT02858336 · CaREFREE Study (Calorie Restriction, Environment and Fitness: Reproductive Effects Evaluation Study)Registry status: CompletedLast update posted: October 16, 2026Query verification: October 16, 2026
NCT05827081 · Phase IIIb Study of Ribociclib + ET in Early Breast CancerRegistry status: RecruitingLast update posted: October 16, 2026Query verification: October 16, 2026
NCT05894239 · A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerRegistry status: RecruitingLast update posted: October 16, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID36378460
October 16, 2026
- SEARCH-PUBMED-gonadorelin
PubMed/MED targeted search: TITLE_ABS:gonadorelin AND TITLE_ABS:randomized
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026